This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cholesterol and colorectal cancer

Authoring team

Cholesterol and Colorectal cancer (CRC)

Lipid imbalance is one of the main risk factors for CRC through associations with inflammation, oxidative stress and insulin resistance (1)

A meta-analysis of prospective studies showed that high levels of serum TG (triglycerides) and TC (total cholesterol) are positively correlated with the incidence rate of CRC, while high levels of serum HDL-C are negatively correlated with CRC incidence rate (1)

  • in this study no association was found between LDL-C and the risk of developing CRC
  • it was noted that the heterogeneity brought about by comparative methods, demographic differences and pathological differences between the research subjects limits the effectiveness of the overall pooled results

Notes:

  • metabolic syndrome (MetS) and colorectal cancer (CRC)
    • MetS is a cluster of metabolic risk factors that includes abdominal obesity, hypertension, hyperglycemia, and dyslipidemia
    • more than 20% of adults are known to have MetS (2)
      • prevalence worldwide varies depending on race, environmental factors, the age and gender composition of the population, genetic differences, physical activity level, eating habits, and differences in measurement standards
    • a study by Lee et al found that MetS is a risk factor for CRC (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.